TV-46000/mdc-IRM 每月或每 2 个月皮下注射一次,以持续提供治.疗水平的利培酮。 2021年9月5日/Bio Valley BIOON/--梯瓦制药(Teva)与MedinCell近日联合宣布,美国食品药品监督管理局(FDA)已接受TV-46000/mdc-IRM(利培酮皮下注射释放注射悬浮液)用于治.疗分裂症的新药申请(NDA)。利培酮是临床常用的分裂症药.物。
and MedinCell (Euronext: MEDCL)announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for TV-46000/mdc-IRM for the treatm
and MedinCell (Euronext: MEDCL)announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Administration...
Teva Pharmaceuticals announced today that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia has been accepted by the U.S. Food and Drug Adminis